Dublin, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/5zb95l/tcell) has announced the addition of the "T-Cell Immunotherapy Market, 2015-2030" report to their offering.
This report provides an extensive study of the field of T-cell immunotherapy. With no marketed products, this emerging field is still in its infancy; the report provides a comprehensive view of the market segmented into the following three sub-groups: CAR-T therapies, TCR therapies and TIL therapies.
The market is characterised by a robust and opportunistic pipeline of products targeting both haematological cancers and solid tumours. As mentioned earlier, several research institutes have played a critical role in progression of the technology to its current stage. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products.
Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania / The Children's Hospital of Philadelphia), JCAR017 (Juno Therapeutics / Seattle Children's Hospital), KTE-C19 and NY-ESO-1 TCR (Kite Pharma / National Cancer Institute), CD19-CAR (Takara Bio / Jichi Medical University) and LN-144 (Lion Biotechnologies / National Cancer Institute). Encouraging clinical results have accelerated the progress of these therapies as they have emerged as one of the most effective ways of leveraging the potential of immune system.
The market is also seeing a growing interest from several technology providers, especially those with capabilities in genome editing and viral and non-viral gene transfer. In addition, several T-cell immunotherapy companies and technology providers are also developing innovative safety switches to manage known side effects such as cytokine release syndrome and B-cell aplasia.
One of the key objectives of the study is to review and quantify the opportunities laid by the innovative programs of both small and big pharma firms. The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms.
Amongst other elements, the report elaborates on the following key areas:
- The current state of the market with respect to key players, development stage of pipeline products (both clinical / preclinical) and targeted indications
- Partnerships which have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product co-development and co-commercialisation
- Innovative technological platforms, such as safety switches, which have contributed significantly in overcoming the existing gaps in therapy regimen
- Various investments and grants received by the companies focused in this area
- Therapeutic areas forming the current focus of developers, the gradual drift and opportunity offered by non-oncological therapeutic areas
- Competitive landscape, challenges and expected trend of market evolution within the three sub-segments
- Development and sales potential based on target consumer segments, likely adoption rate and expected pricing
Key Topics Covered:
1 Preface
2 Executive Summary
3 Introduction
4 Market Landscape
5 Chimeric Antigen Receptor-T Cell Therapy
6 T-Cell Receptor (Tcr) Therapies
7. Tumour Infiltrating Lymphocytes (Til) Based Therapies
8. Market Opportunity
9. Key Therapeutic Areas For T-Cell Therapies
10 Emerging Technologies
11 Venture Capital Support
12 Company Profiles
13 Interview Transcripts
14 Conclusion
15. Appendix I: Tabulated Data
Appendix Ii: List Of Companies And Organizations
Companies Mentioned
- Abingworth
- Abramson Cancer Center, University of Pennsylvania
- Acorn Campus Ventures
- Adaptimmune
- AFA Försäkring
- AGF Private Equity
- AgonOx
- Agreen Biotech
- Aju IB Investment
- Alaska Permanent Fund
- Alexandria Ventures
- Allos Therapeutics
- Altor BioScience
- Amgen
- Applied Immune Technologies
- Aquilo Capital Management
- ARCH Venture Partners
- Artax Biopharma
- AstraZeneca
- Atara Biotherapeutics
- Atlas Venture
- Autolus (spin off from UCL)
- AVG Ventures
- Banca Esperia
- BankInvest Biomedical Venture
- Bayer
- Baylor College of Medicine
- Bellicum Pharmaceuticals
- Bezos Expeditions
- Biogen
- BioNTech
- Biotecnol
- bluebird bio
- Bpifrance
- Brace Pharma Capital
- Bristol-Myers Squibb
- Broad Institute
- Broadfin Capital
- Cabaret Biotech
- California Institute for Regenerative Medicine
- California Institute of Technology
- California Stem Cell Agency
- Cancer Prevention and Research Institute of Texas
- Caribou Sciences
- CARsgen
- Casdin Capital
- Catalyst
- Celdara
- Celgene
- Cell Therapy Catapult
- Cellectis
- CELLforCURE
- Cellular Biomedicine Group
- Cellular Therapeutics
- Celyad
- Children with Leukaemia
- Chinese PLA General Hospital
- City of Hope Medical Center
- CLL Global Research Foundation Alliance
- Cold Genesys
- Conkwest
- Cowen Investment
- CRISPR Therapeutics
- CrunchFund
- Cyto Pulse
- Dartmouth College
- Deerfield Partners
- Dendreon Corporation
- Deutsche Krebshilfe
- Duke University
- Easton Capital
- EcoR1 Capital
- Editas Medicine
- Edmond Venture Capital
- Ehime University
- Eisai
- Eli Lilly
- Endocyte
- Erasmus University
- Eureka Therapeutics
- Fate Therapeutics
- Felicis Ventures
- Fidelity Biosciences
- Fiverings Co.
- Flagship Ventures
- Forbion Capital Partners
- Foresite Capital
- Formula Pharmaceuticals
- Fred Hutchinson Cancer Research Center
- Fujita Health University
- GammaCell Biotechnologies
- Genentech
- Genzyme (Sanofi)
- Genzyme Ventures
- Gilead Sciences
- GlaxoSmithKline
- Google Ventures
- Griffin Securities
- H. Lee Moffitt Cancer Center and Research Institute
- Harbinger Venture Capital
- Harvard University
- Healthcare investment company Syncona
- Heat Biologics
- Herlev Hospital
- High Line Venture Partners
- ImmunoCellular Therapeutics
- Immunocore
- Imperial Innovations
- IMS Health Capital
- Innovative Genome Initiative
- Intellia Therapeutics
- Intrexon
- Iowa State University
- Jannsen Biotech
- Jennison Associates
- Jichi Medical University
- JMP Securities
- John Hopkins University
- John Wayne Cancer Institute
- Jonsson Comprehensive Cancer Center
- JP Moulton Charitable Foundation
- Juno Therapeutics
- Karolinska University Hospital
- Keio University, School of Medicine
- Khosla Ventures
- Kite Pharma
- Leiden University Medical Center
- Leukemia and Lymphoma Society
- Ligand Pharmaceuticals
- Lion Biotechnologies
- Lonza Biologics
- Loyola University
- M.D. Anderson Cancer Center
- Massachusetts Institute of Technology
- MaxCyte
- Mayo Clinic
- Medigene
- Memorial Sloan Kettering Cancer Center
- Merck
- Merck Serono
- Mie University
- Millennium Pharmaceuticals
- MolMed
- Monash University
- Morphotek
- Mustang Therapeutics
- Nagoya University
- Nantes University Hospital
- Nantworks
- National Cancer Institute
- National Institute of Health
- National University of Singapore
- NeoStem
- New Enterprise Associates (NEA)
- New Leaf Venture
- Novartis
- Novartis Institute for Biomedical Research (NIBR)
- Novo A/S
- Oberland Capital Healthcare
- ODYSSEE Venture
- Ohio University
- Omega Funds
- Oncodesign Biotechnology
- OnCyte
- Ono Pharmaceutical Co.
- Onyx Pharmaceuticals
- Opexa Therapeutics
- Opus Bio
- OrbiMed Advisors
- Oxford BioMedica
- Partners Innovation Fund
- Pasteur Institute
- Peking University
- Perceptive Advisors
- Peter MacCallum Cancer Centre, University of Melbourne
- Pfizer
- Pharmacyclics
- Polaris Partners
- Pontifax
- Precision Biosciences/Pregenen
- Precision Genome Engineering
- Progenitor Cell Therapy
- Pure MHC
- QueensBridge Venture Partners
- Quogue Capital
- QVT Financial
- RA capital Management
- Ramius Capital Group
- Redmile Group
- Remeditex Ventures
- Renji Hospital
- Ridgeway Capital Partners
- Riverbank Capital Securities
- Roche
- Rock Spring Capital
- Roswell Park Cancer Institute
- Sabby Capital
- San Raffaele Hospital (OSR)
- Sanderling Ventures
- Sangamo Biosciences
- Sanofi-Genzyme BioVentures
- Seattle Children's Hospital
- Seattle Genetics
- Sectoral Asset Management
- Servier
- Shanghai Cancer Institute
- Sheba Medical Center
- Shenzhen Second People's Hospital
- Shionogi
- Silicon Valley Bank
- Sorrento Therapeutics
- Southwest Hospital
- Spectrum Pharmaceuticals
- SR One
- St. Jude Children's Research Hospital
- Stage Cell Therapeutics
- Statcom Co.
- Suma Ventures
- Sun Yat-Sen University
- Sunol Molecular Corporation
- SV Angel
- Swedish Cancer Society
- T. Rowe Price Associates
- Takara Bio
- T-Cell Factory
- Tel Aviv Sourasky Medical Centre
- TETHYS
- Texas Children's Hospital
- The Children's Hospital of Philadelphia
- The Christie NHS Foundation Trust
- The Methodist Hospital System
- The Netherlands Cancer Institute
- Theravectys
- Thermo Fisher Scientific
- Third Rock Ventures
- Three Arch Opportunity Fund
- TILT Biotherapeutics
- TNK Therapeutics (wholly owned subsidiary of Sorrento Therapeutics)
- Transposagen Biopharmaceuticals
- TVM Capital
- Two Blades Foundation
- TxCell
- University College of London
- University Health Network
- University of California
- University of Connecticut
- University of Florida
- University of Milano-Bicocca
- University of Minnesota
- University of Oxford
- Perelman School of Medicine, University of Pennsylvania
- University of Southern California
- University of Zurich
- Unum Therapeutics
- Uppsala University
- Valeant Pharmaceuticals
- venBio
- Venrock
- Versant Ventures
- Viking Global Investors
- Weill Cornell Medical College
- Weizmann Institute of Science
- Wellington Management
- X-Body
- Y Combinator
- Yuan Capital
- ZIOPHARM Oncology
For more information visit http://www.researchandmarkets.com/research/5zb95l/tcell